Overview
ARA-290 (Cibinetide) is a synthetic, non-hematopoietic peptide engineered from the structure of erythropoietin (EPO). It selectively binds to the innate repair receptor (IRR) to modulate immune responses, reduce inflammation, and promote tissue healing without stimulating red blood cell production. By targeting specific inflammatory pathways, the ARA-290 peptide offers significant therapeutic potential for managing neuropathic pain, protecting transplanted tissues, and addressing complications associated with diabetes and sarcoidosis.
Potential Benefits
- Neuropathic Pain Relief: Clinical trials demonstrate that ARA-290 significantly improves symptoms of small fiber neuropathy in patients with sarcoidosis and type 2 diabetes (Dahan A et al., 2013).
- Anti-Inflammatory Action: The peptide dampens innate immune cell functions and macrophage activation, showing efficacy in ameliorating experimental colitis (Nairz M et al., 2017).
- Metabolic Control in Diabetes: Research indicates that ARA-290 improves metabolic control and reduces neuropathic symptoms in patients with type 2 diabetes (Brines M et al., 2015).
- Tissue Protection and Engraftment: Cibinetide protects isolated human islets in stressful environments, preventing damage and improving engraftment success during transplantation (Yao M et al., 2021).
- Nerve Fiber Regeneration: Studies show the peptide can increase corneal nerve fiber density, indicating active nerve repair and regeneration (van Velzen M et al., 2014).